The Science Advisory Board Immunology Insider

November 17, 2020 -- The Science Advisory Board Immunology Insider

Science Advisory Board Immunology Insider
Web Version
November 17, 2020
Immunology Insider
Sponsored by Beckman Coulter
Forward Email

Dear Immunology Insider,

Welcome to the next edition of ScienceBoard's Immunology Insider! Leaps and bounds of progress have been made in many areas of immunology since our last newsletter.

To begin with, immunology has been central for understanding host immune responses to SARS-CoV-2. Recently, immunologists from Vanderbilt University Medical Center and Columbia University have been working to understand why children respond differently to the virus and seem to be more protected than adults. This work may lead to new avenues of therapeutic development.

Other questions about COVID-19 that immunology research is helping to answer include the following:

In terms of COVID-19 vaccines, recent updates from Pfizer/BioNTech and Moderna phase III clinical trials claim that each candidate is highly protective against infection. Some companies have not experienced such a smooth road. The U.S. Food and Drug Administration (FDA) held back COVID-19 vaccine clinical trials of early front-runners Inovio and Johnson & Johnson in September and October, respectively. Both trials have since been restarted.

Besides these companies, others are working on early-stage development and immunogenicity studies. These include candidates from BioVaxys, ImmunityBio, ImmunoPrecise, Ufovax, and Axon Neuroscience, among others.

Also, an entirely new class of COVID-19 vaccines is beginning to emerge. Until recently, most vaccines under development have consisted of DNA/RNA or protein subunit-based platforms. Now, Tonix Pharmaceuticals is advancing its modified live-attenuated COVID-19 vaccine candidate into early clinical trials.

For comprehensive coverage of COVID-19 vaccines, please visit the Vaccines section of our Immunology Community.

Beyond COVID-19, there have been many advancements in basic immunology research in the past months. A new study identified bidirectional metabolic control over the function of effector regulatory T cells that may help identify new targets for autoimmune diseases. A group from the Massachusetts Institute of Technology has developed a massively parallel single-cell RNA sequencing protocol that allows scientists to extract 10 times more information from a single cell.

And researchers have found that combining two monoclonal antibody treatments can increase the effectiveness of cancer immunotherapies by blocking the immunosuppressive effects of regulatory T cells in tumor cells.

We would love to hear about your work related to immunology. Email us today and let us know!

Samantha Black, PhD
The Science Advisory Board Editor

Immunology Community  

Metabolic control of Tregs is critical for immune tolerance

Why are children more resistant to SARS-CoV-2 infection?

Moderna reports 94.5% efficacy for COVID-19 vaccine

Cytiva helps Clover scale up biomanufacturing of COVID-19 vaccine

Abpro's neutralizing COVID-19 mAb shows efficacy in monkeys

Tonix touts positive preclinical COVID-19 vaccine results

Inovio begins late phase clinical trials for COVID-19 vaccine

U.S. government expands assistance to J&J COVID-19 vaccine research

Why the most common SARS-CoV-2 strain spreads so easily

EMA recommends approval of Roche's mAb breast cancer product

Proteintech, HebeCell to develop cancer immunotherapies

Moderna finalizes interim results for COVID-19 vaccine

IsoPlexis launches new personalized lab systems

Medicago, GSK begin phase II/III trial of adjuvanted COVID-19 vaccine

BioVaxys' COVID-19 vaccine shows positive early results

Sorrento to file IND for anti-SARS-CoV-2 nasal drops

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine

Can vaccine resistance be predicted with test samples?

BrickBio expands antibody-drug conjugate programs

Fina Biosolutions nabs EU patent for conjugate vaccine platform

ImmunityBio COVID-19 vaccine shows positive clinical results

FDA grants Lilly EUA for its COVID-19 mAb

Pfizer, BioNTech tout positive results for COVID-19 vaccine

If successful, COVID-19 vaccines could be worth $27B

Pierre Fabre initiates trial for mAb to treat solid tumors

Different immune response helps kids clear SARS-CoV-2 quickly

Senhwa to begin phase II trial of COVID-19 drug

Humanigen, DOD develop COVID-19 mAb

ABL Europe collaborates on SARS-CoV-2 vaccine

ProteoNic licenses tech to Gilead for biologics production

Synthetic nanobodies show potential for new COVID-19 therapies

Avidea publishes data on improved efficacy of IV-delivered cancer vaccines

XNK gets orphan drug nod from FDA

ImmunoPrecise, Mila partner on antibody therapeutics

European org issues guidance for viral vector COVID-19 vaccines

Samsung Biologics partners on antibody development, manufacturing

TFF, Augmenta Bioworks partner on COVID-19 mAbs

Immunic completes COVID-19 immunotherapy phase II trial enrollment

Independent monitoring committee recommends halting REGN-COV2 trial

Effectiveness of COVID-19 vaccines will rely on public trust

Most antibody responses to SARS-CoV-2 are strong and long-lasting

Eppendorf introduces adjustable-spacing pipettes

Takeda expands COVID-19 vaccine supply with Moderna, Japan

Emulate to provide FDA with 'lung chips' to evaluate COVID-19 vaccines

New model could improve vaccine, immunotherapy design

Merck invests $1B in Seagen

Eli Lilly to supply U.S. with 300,000 doses of anti-SARS-CoV-2 antibody

GCAR begins COVID-19 clinical trials

Nektar plans clinical trial for COVID-19 treatment

Sumitomo Dainippon commences cancer immunotherapy trial

ImmunoPrecise, Twist collaborate on novel therapeutics

Genome & Company doses patients in immuno-oncology microbiome therapeutic trial

New COVID-19 immunogen could help with early diagnosis

Who should get the 1st COVID-19 vaccines?

HiFiBiO advances trial of SARS-CoV-2 neutralizing antibodies

BioInvent to start clinical trial of anticancer antibody treatment

NBE Therapeutics begins clinical trial of antibody-drug conjugate

Kezar gets orphan drug nod for immunoproteasome inhibitor

BD names new executive vice presidents

Researchers identify 'ancient' DNA weapons against cancer

ImmunityBio, NantKwest launch COVID-19 vaccine trial

Amyris, IDRI to partner on RNA vaccines

Thermo Fisher's Q3 earnings boosted by COVID-19 sales

Poseida, TScan partner on allogenic TCR therapies for COVID-19

Immunic gets funding for lead COVID-19 therapeutic candidate

Proteintech acquires ChromoTek

HJF to develop herpes virus vaccines

Aridis touts positive preclinical results for COVID-19 mAb treatment

Akron, Synairgen partner on IFN-beta treatment for COVID-19

Ultimovacs touts positive early clinical results for universal cancer vaccine

Bristol Myers Squibb advances cancer immunotherapy in Europe

CHMP recommends approval for Janssen's mAb in psoriatic arthritis

NIH initiates ACTIV trial for COVID-19 immune modulators

How are asymptomatic COVID-19 carriers different from symptomatic patients?

Precigen nabs FDA nod for manufacturing UltraCAR-T therapies

ImmunityBio begins phase I trial for its COVID-19 vaccine candidate

Eiger touts positive results for COVID-19 therapy

New method reclaims resolution of single-cell RNA-seq

Thermo Fisher to add sterile filling lines in Singapore

Atum licenses cell line development tools to Rentschler Biopharma

Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies

Moderna gets nod from EMA to submit marketing authorization

J&J pauses COVID-19 vaccine trials

Lineage Cell, Cancer Research U.K. advance cancer vaccine

Can SARS-CoV antibodies be used to develop universal coronavirus vaccines?

Targovax granted European patent for cancer immunotherapy

AuraVax licenses intranasal vaccine platform

Oncopeptides moves to file for regulatory approvals

Glycostem gets orphan drug nod for multiple myeloma cell therapy

Long-lasting IgG antibodies found in blood and saliva of COVID-19 patients

Grifols begins trial for SARS-CoV-2 hyperimmune globulin

Will mutation of the SARS-CoV-2 virus affect vaccine effectiveness?

Moderna secures $56M for mobile vaccine manufacturing

Abveris, Immunitas partner on mAbs discovery

Lilly to supply COVID-19 therapy to low-income nations

J&J to supply EU with 200M COVID-19 vaccine doses

NCI launches SeroNet

FDA issues guidance on submitting EUA requests for COVID-19 vaccines

EMA to review BioNTech, Pfizer's SARS-CoV-2 vaccine

Eli Lilly seeks EUA from FDA for its SARS-CoV-2 mAbs

Send your press release to

 Do not reply to this e-mail as it was sent from an unmonitored account.
Unsubscribe from the SAB Announcements.
Reset your password.
Contact support. Privacy Policy.
Email sent to: ., 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA - (520) 298-1000
Copyright 2020 All Rights Reserved.

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter